Clinical Trials Logo

Alzheimer Disease clinical trials

View clinical trials related to Alzheimer Disease.

Filter by:

NCT ID: NCT05497817 Not yet recruiting - Dementia Clinical Trials

A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia

Start date: September 2022
Phase: N/A
Study type: Interventional

This research is being done to develop a unique matching process for caregivers of persons living with dementia, such as Alzheimer's disease, Lewy body dementia, frontotemporal degeneration, or other dementia syndromes. Dementia caregivers often assume greater caregiving burden than do non-dementia caregivers, and the caregiving duration tends to be longer. Many caregivers do not have the adequate support they need. Peer-to-peer support has been shown to improve quality of life, increase use of services, improve caregiver health, and reduce hospitalizations in the person they are caring for. This study will assess a technology platform and matching process for the purpose of peer-to-peer emotional support aimed at improving overall wellbeing in dementia care partners/caregivers.

NCT ID: NCT05491902 Terminated - Alzheimer Disease Clinical Trials

Pilot PET Study of Regional Cerebral Protein Synthesis in Alzheimer's

Start date: October 9, 2017
Phase:
Study type: Observational

Measuring the rate of cerebral protein synthesis (rCPS) may enable us to better-understand the progression of Alzheimer's Disease (AD). This study is using a new method of measuring rCPS non-invasively, and to offer new approaches to the assessment of new therapeutic strategies in clinical trials. Previous studies have established the utility of [11C]-Leucine PET to assess the rCPS. This study will use [11C]- Leucine PET to measure rCPS in AD patients versus age-matched and young healthy subjects to determine whether a measurable difference exists. The study will involve participants receiving up to two PET scans, a structural MRI scan. The PET scanning procedures will involve some withdrawal of blood samples. The ultimate goal of this proposal is to indicate new routes for treatment of AD.

NCT ID: NCT05482867 Not yet recruiting - Clinical trials for Probable Alzheimer's Disease

Exploratory Open Label Study for Development of a Method To Detect Dendritic Cells

Start date: August 15, 2022
Phase:
Study type: Observational

This is a proof-of-concept study designed to confirm that human phagocytic cells can be labeled with the near-infrared dye indocyanine green (ICG) and the presence of the labeled cells 48 hours later in cerebral cortex can be inferred using near infrared spectroscopy (NIRS).

NCT ID: NCT05478681 Not yet recruiting - Alzheimer Disease Clinical Trials

Home-based Transcranial Direct Current Stimulation (tDCS) for Behavioral Symptoms in Alzheimer's Disease and Related Dementias (ADRD)

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess acceptability, and safety of providing tDCS to ADRD patients with behavioral symptoms and to assess the efficacy of tDCS for ADRD-related symptoms, mainly behavioral symptoms.

NCT ID: NCT05478031 Recruiting - Alzheimer Disease Clinical Trials

A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease

Start date: June 7, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to measure effects on CSF biomarkers, EEG and safety with REM0046127 oral suspension compared with placebo in subjects with mild to moderate Alzheimer disease. - The study duration will be up to 2 months for each treated subject - Each subject will start with a 14-day placebo run-in period, followed by a 28-day treatment period and 7-day follow-up period - Visit frequency: every week - Number of Subjects: at least 30 subjects with an upper limit of 60 subjects. - Study Arms and Duration: All subjects will be randomized (1:1:1 allocation) to one ofthree different starting levels after the 14-day run-in period: - REM0046127 high dose: 1400mg (700mg bid) oral suspension per day for 28 days - REM0046127 low dose: 350mg (175mg bid) oral suspension per day for 28 days - Placebo: placebo oral suspension bid for 28 days

NCT ID: NCT05477862 Not yet recruiting - Alzheimer Disease Clinical Trials

Neural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's Disease

Start date: August 15, 2022
Phase: Early Phase 1
Study type: Interventional

Clinically Designed Improvisatory Music (CDIM) is a form of improvised music based on calm-inducing sound parameters which brought relief to our cohort of neurology patients. As a direct sound-based approach, CDIM does not rely on autobiographical memory and may have wider applicability and generalizability. We wish to examine if CDIM decreases anxiety in 15 cognitively healthy individuals and 15 Alzheimer Disease patients with anxiety (AD-A).

NCT ID: NCT05477056 Enrolling by invitation - Alzheimer Disease Clinical Trials

Quality Improvement PrecivityAD Clinician Survey (QUIP I)

QUIP I
Start date: March 1, 2021
Phase:
Study type: Observational

There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia. MCI impacts 12-18% of people in the United States over age 60 and is often an initial clinical sign of Alzheimer's disease (AD) (Alzheimer's Association, 2022). The PrecivityAD test is an analytically and clinically validated blood test that aids healthcare providers in the diagnosis of AD in patients with MCI and early-stage dementia. C2N has created a quality improvement (QI) survey to gather insight from clinicians as to the clinical effectiveness of the commercially available PrecivityAD™ test, which identifies whether a patient with signs and symptoms of cognitive decline is likely to have amyloid plaques in the brain, a pathological hallmark of Alzheimer's disease.

NCT ID: NCT05476783 Not yet recruiting - Alzheimer's Disease Clinical Trials

An Open-label Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease.

Start date: August 2022
Phase: Phase 2
Study type: Interventional

This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) and is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to approximately 113 weeks.

NCT ID: NCT05475158 Completed - Alzheimer Disease Clinical Trials

Comparison of OCTA Factors in Patients With or Without Amyloid Pathology: A Prospective Study

Start date: September 1, 2019
Phase:
Study type: Observational

To compare alternation of retinal microcirculation within the macula and optic disc in patients with dementia, mild cognitive impairment (MCI), and cognitively healthy subjects who had positive amyloid biomarkers (Aβ +) or not, using optical coherence tomography angiography (OCTA).

NCT ID: NCT05469360 Not yet recruiting - Alzheimer Disease Clinical Trials

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Start date: September 9, 2022
Phase: Phase 1
Study type: Interventional

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)